Board & Executive

Dr Neil MacGilp

Neil has a full career of consumer and healthcare product innovation experience, mostly as R&D Director with Procter & Gamble and latterly as Group Technical Director with SABMiller PLC. Most recently he founded NAM Innovation Ltd, a consultancy dedicated to technology and innovation coaching. He has a proven track record of transforming technology into commercially successful products and has been on the Ambicare Board since 2011.

Ron Petersen

Investor Director – Longbow Capital
Ron is a co-founder and designated partner of Longbow, providing management assistance to portfolio companies and reviewing new business opportunities. Ron has acted, as the Managing Director of the Boots Centre for Innovation and CEO of CyDen Ltd.
Ron is also the Investor Director at Calon and Ambicare.
Ron possesses almost four decades of industrial management experience spent over 20 years with Armstrong World Industries, managing global businesses from its London base. In 1992, Ron began to specialise in turning underperforming or early stage companies into profitable and valued concerns. Examples of companies with which he has been involved in this way include Insituform Group Ltd., Bridon plc, Brunel Holdings plc, and Oystertec plc. He was also a founder and Chairman of NanoBeam Ltd., a successful nanotechnology device company in Cambridge.

Graeme Low

Chief Executive Officer
Graeme is a Chartered Management Accountant with over 12 years’ experience in the life science sector. This includes 6 years as Finance Director and General Manager of a contract research organisation (CRO) and also working at Shield Diagnostics (in-vitro diagnostics) and GSK (bulk active manufacture). He was heavily involved in the management buyout of a University of Dundee spin out in 2005. Graeme also holds an MBA.

Dr Andrew McNeill

Chief Scientific Officer
As a part of the initial start-up team, Andrew has been instrumental in the development of the Ambicare products, CE marking and company accreditation to ISO 13485. He also has extensive experience in IP creation and management. Prior to joining Ambicare, Andrew was a postdoctoral scientist at St Andrew’s University, researching new lighting technologies for dermatology applications; this research was the foundation for the start of the company. He also holds an honorary research fellowship at Ninewells Hospital, Dundee.

Company advisers

Professor James Ferguson

Until his recent retirement Professor Ferguson was Consultant Dermatologist and Head of the University Department of Dermatology in Dundee; he was also responsible for the Scottish Photobiology Diagnostic and Treatment Advice Unit, which houses the Scottish Photodynamic therapy centre.
He has published extensively in the field of photodermatology (>200 peer reviewed publications) . His MD thesis was on the subject of Drug-induced Photosensitivity.

Professor Ifor Samuel

Professor Samuel is Director of Research at the School of Physics and Astronomy at the University of St Andrews. He leads the Organic Semiconductor Centre and his research focusses on optoelectronic materials and their applications, including in biology and medicine. Research highlights include the development of highly efficient solution-processed light-emitting diodes (LEDs), compact plastic lasers, and the use of organic LEDs in medicine in collaboration with Prof Ferguson. His work is internationally recognised and his scientific output includes more than 300 refereed journal articles and more than 20 patents.

Paul Donnelly

Business Development
Paul has 28 years’ experience in all facets of leadership within the medical devices sector. He is a seasoned corporate and private equity international business builder with experience in managing start-ups, turnarounds and growth. He has also led two successful exits of Cremascoli Orthopaedics and SSL Medical, and an IPO (Puricore plc).